- Conditions
- Alcohol Use Disorder
- Interventions
- Dexamethasone Oral, Placebo
- Drug
- Lead sponsor
- Stony Brook University
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Stony Brook, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 44
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Multiple Myeloma
- Interventions
- Radium-223 dichloride (Xofigo, BAY88-8223), Placebo, Bortezomib, Dexamethasone
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 10
- States / cities
- Scottsdale, Arizona • Little Rock, Arkansas • Encinitas, California + 7 more
- Conditions
- Hyperandrogenemia, Obesity, Polycystic Ovary Syndrome
- Interventions
- Hydrocortisone, dexamethasone, Cosyntropin, rhCG
- Drug
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 7 Years to 16 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Bronchopulmonary Dysplasia
- Interventions
- Dexamethasone Early, Dexamethasone Late
- Drug
- Lead sponsor
- NICHD Neonatal Research Network
- Network
- Eligibility
- 13 Days to 15 Days
- Enrollment
- 371 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1992 – 1994
- U.S. locations
- 13
- States / cities
- Palo Alto, California • New Haven, Connecticut • Washington D.C., District of Columbia + 10 more
- Conditions
- Recurrent Multiple Myeloma, Refractory Multiple Myeloma
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Carfilzomib, Computed Tomography, Dexamethasone, FDG-Positron Emission Tomography, Fludeoxyglucose F-18, Pomalidomide, Teclistamab
- Procedure · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2029
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Acute Lymphoblastic Leukemia, Acute Lymphoblastic Lymphoma
- Interventions
- Prednisone, Vincristine, Daunorubicin, Pegaspargase, Erwinase®, Cyclophosphamide, Cytarabine, Mercaptopurine, Dasatinib, Methotrexate, Blinatumomab, Ruxolitinib, Bortezomib, Dexamethasone, Doxorubicin, Etoposide, Clofarabine, Vorinostat, Idarubicin, Nelarabine, Thioguanine, Asparaginase Erwinia chrysanthemi (recombinant)-rywn, Calaspargase Pegol
- Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 1 Year to 18 Years
- Enrollment
- 790 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2028
- U.S. locations
- 7
- States / cities
- Palo Alto, California • San Diego, California • Peoria, Illinois + 4 more
- Conditions
- Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
- Interventions
- Dexamethasone, Vincristine, Inotuzumab, Blinatumomab, Dasatinib, IT MHA, Cyclophosphamide, Cytarabine, Methotrexate, 6-Mercaptopurine, Calaspargase, Daunorubicin, Thioguanine
- Drug · Procedure
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 1 Year to 18 Years
- Enrollment
- 128 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2034
- U.S. locations
- 3
- States / cities
- Charlotte, North Carolina • Tulsa, Oklahoma • Memphis, Tennessee
- Conditions
- Pancreatic Cancer, Hepatocellular Cancer, Mesothelioma, Breast Cancer, Gastric Cancer, Esophageal Cancer, Nasopharyngeal Cancer, Kidney Cancer, Squamous Cell Cancer of Head and Neck (SCCHN), Non-small Cell Lung Cancer (NSCLC), Non-squamous
- Interventions
- TAK-500, Pembrolizumab, Tocilizumab, Dexamethasone
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Duarte, California • La Jolla, California + 9 more
- Conditions
- ACL, ACL Injury, Anterior Cruciate Ligament Injury, Anterior Cruciate Ligament Rupture, Anesthesia
- Interventions
- Acupuncture + Standard of Care
- Other
- Lead sponsor
- Hospital for Special Surgery, New York
- Other
- Eligibility
- 12 Years to 80 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Relapsed or Refractory Multiple Myeloma
- Interventions
- Carfilzomib, Dexamethasone, Pomalidomide
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Denver, Colorado • New Haven, Connecticut + 8 more
- Conditions
- Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma, RISS Stage II Plasma Cell Myeloma
- Interventions
- Bortezomib, Daratumumab and Hyaluronidase-fihj, Dexamethasone, Lenalidomide, Quality-of-Life Assessment
- Drug · Biological · Other
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 1,450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 640
- States / cities
- Anchorage, Alaska • Phoenix, Arizona • Tucson, Arizona + 456 more
- Conditions
- Carcinoma, Non Small Cell Lung
- Interventions
- Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®), Placebo, Docetaxel (Taxotere®), Dexamethasone (pre- and post-medication for docetaxel)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 913 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Acute Lymphoblastic Leukemia in Complete Remission, Lymphoblastic Lymphoma in Complete Remission, Mixed Phenotype Acute Leukemia in Complete Remission
- Interventions
- Ixazomib
- Drug
- Lead sponsor
- Ehab L Atallah
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Non-hodgkin Lymphoma, Hodgkin Lymphoma
- Interventions
- DOC Group B, Pv-COMRAD 1 and 2 Group B, Pv-R-CYM 1 and 2 Group B, DOC Group C, MAD CPR 1 and 2, Pv-R CYVE 1 and 2, Pv-R CYVE-MTX 1 and 2, MAD CP, Pv-Cytarabine/etoposide, AD CP, Bv-AVD-R 1 and 2: COHORT IIa, Bv-NVD-R, Cycle 1-2, Bv-NVD-R, Cycle 1-4 SER, Bv-AVD-R, Bv-NVD-R, Cycle 1-4 RER, Bv-NAVD-R, Cycle 1-2, Involved Site Radiation Therapy
- Drug · Radiation
- Lead sponsor
- New York Medical College
- Other
- Eligibility
- 3 Years to 39 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Gainsville, Florida • Vallhala, New York
- Conditions
- Pain, Postoperative
- Interventions
- Methadone Hydrochloride, Standard pain regimen, Spinal Fusion Surgery, Dexamethasone, Ketamine, Remifentanil, Sufentanil
- Drug · Other · Procedure
- Lead sponsor
- Montefiore Medical Center
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Alzheimer's Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders
- Interventions
- Donanemab, Placebo, Dexamethasone
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 60 Years to 85 Years
- Enrollment
- 1,175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 43
- States / cities
- Chandler, Arizona • Irvine, California • Long Beach, California + 38 more
- Conditions
- Leukemia
- Interventions
- cytarabine, dexamethasone, etoposide, idarubicin, ifosfamide, leucovorin calcium, mesna, pegaspargase, therapeutic hydrocortisone, thioguanine, vincristine sulfate, low-LET cobalt-60 gamma ray therapy, low-LET electron therapy, low-LET photon therapy, Methotrexate
- Drug · Radiation
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 20 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2006
- U.S. locations
- 30
- States / cities
- Long Beach, California • Los Angeles, California • Orange, California + 23 more
- Conditions
- Bronchopulmonary Dysplasia, Respiratory Distress Syndrome, Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature
- Interventions
- Minimal mechanical ventilation management, Routine mechanical ventilation management, Dexamethasone, Placebo
- Procedure · Drug
- Lead sponsor
- NICHD Neonatal Research Network
- Network
- Eligibility
- 5 Minutes to 10 Days
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2002
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Palo Alto, California • New Haven, Connecticut + 10 more
- Conditions
- Leiomyosarcoma, Uterine Neoplasm
- Interventions
- gemcitabine, docetaxel, doxorubicin
- Drug
- Lead sponsor
- Sarcoma Alliance for Research through Collaboration
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 12
- States / cities
- Washington D.C., District of Columbia • Tampa, Florida • Atlanta, Georgia + 8 more
- Conditions
- Multiple Myeloma in Relapse, Multiple Myeloma
- Interventions
- Ulocuplumab, Lenalidomide, Bortezomib, Dexamethasone
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Multiple Myeloma
- Interventions
- Radium-223 dichloride (Xofigo, BAY88-8223), Placebo, Bortezomib, Dexamethasone
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 3
- States / cities
- Encinitas, California • Winston-Salem, North Carolina • Seattle, Washington
- Conditions
- Hodgkin Disease
- Interventions
- ABVE-PC, DECA
- Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- Not listed
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Major Depressive Disorder
- Interventions
- DEX-CRF stimulation test, Psychosocial stress induction, Brain imaging of sad mood , self-reference, reward, Acoustic startle
- Drug · Behavioral · Procedure
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 113 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2011
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Optic Neuritis, Myelitis, Myelitis, Transverse
- Interventions
- High-dose corticosteroids (HDCS), High-dose corticosteroids (HDCS) and PLEX
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 382 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 35
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Loma Linda, California + 27 more